Department of Pharmaceutics, China Pharmaceutical University, 24 TongJiaXiang, Nanjing, 210009, People's Republic of China.
Minigene Pharmacy Laboratory, China Pharmaceutical University, Nanjing, People's Republic of China.
Diabetologia. 2018 Jun;61(6):1384-1396. doi: 10.1007/s00125-018-4593-3. Epub 2018 Mar 15.
AIMS/HYPOTHESIS: The intestinal immune system is an ideal target to induce immune tolerance physiologically. However, the efficiency of oral protein antigen delivery is limited by degradation of the antigen in the gastrointestinal tract and poor uptake by antigen-presenting cells. Gut dendritic cells (DCs) are professional antigen-presenting cells that are prone to inducing antigen-specific immune tolerance. In this study, we delivered the antigen heat shock protein 65-6×P277 (H6P) directly to the gut DCs of NOD mice through oral vaccination with H6P-loaded targeting nanoparticles (NPs), and investigated the ability of this antigen to induce immune tolerance to prevent autoimmune diabetes in NOD mice.
A targeting NP delivery system was developed to encapsulate H6P, and the ability of this system to protect and facilitate H6P delivery to gut DCs was assessed. NOD mice were immunised with H6P-loaded targeting NPs orally once a week for 7 weeks and the onset of diabetes was assessed by monitoring blood glucose levels.
H6P-loaded targeting NPs protected the encapsulated H6P from degradation in the gastrointestinal tract environment and significantly increased the uptake of H6P by DCs in the gut Peyer's patches (4.1 times higher uptake compared with the control H6P solution group). Oral vaccination with H6P-loaded targeting NPs induced antigen-specific T cell tolerance and prevented diabetes in 100% of NOD mice. Immune deviation (T helper [Th]1 to Th2) and CD4CD25FOXP3 regulatory T cells were found to participate in the induction of immune tolerance.
CONCLUSIONS/INTERPRETATION: In this study, we successfully induced antigen-specific T cell tolerance and prevented the onset of diabetes in NOD mice. To our knowledge, this is the first attempt at delivering antigen to gut DCs using targeting NPs to induce T cell tolerance.
目的/假设:肠道免疫系统是诱导生理性免疫耐受的理想靶点。然而,口服蛋白抗原的递送效率受到抗原在胃肠道中的降解和抗原呈递细胞摄取能力差的限制。肠道树突状细胞(DCs)是易于诱导抗原特异性免疫耐受的专业抗原呈递细胞。在这项研究中,我们通过口服负载抗原热休克蛋白 65-6×P277(H6P)的靶向纳米颗粒(NPs)将抗原直接递送至 NOD 小鼠的肠道 DCs,并研究了这种抗原诱导免疫耐受以预防 NOD 小鼠自身免疫性糖尿病的能力。
开发了一种靶向 NP 递药系统来包载 H6P,并评估了该系统保护和促进 H6P 递送至肠道 DCs 的能力。NOD 小鼠每周口服免疫 H6P 负载的靶向 NPs 一次,共 7 周,并通过监测血糖水平评估糖尿病的发病情况。
负载 H6P 的靶向 NPs 保护了包封的 H6P 免受胃肠道环境中的降解,并显著增加了 H6P 在肠道派尔集合淋巴结(PP)中 DC 的摄取(与对照 H6P 溶液组相比,摄取量增加了 4.1 倍)。口服 H6P 负载的靶向 NPs 可诱导抗原特异性 T 细胞耐受,并预防 100%的 NOD 小鼠发生糖尿病。免疫偏离(辅助性 T 细胞[Th]1 向 Th2)和 CD4CD25FOXP3 调节性 T 细胞被发现参与了免疫耐受的诱导。
结论/解释:在这项研究中,我们成功地诱导了 NOD 小鼠的抗原特异性 T 细胞耐受,并预防了糖尿病的发生。据我们所知,这是首次尝试使用靶向 NPs 将抗原递送至肠道 DCs 以诱导 T 细胞耐受。